Predicting the risk of XXXX due to nonsteroidal antiinflammatory drugs: NSAID electronic assessment of risk.

@entity1 @entity229 @entity360
OBJECTIVE: To validate that, using @entity1 demographics and other risk factors readily obtained from computerized databases, one can predict a priori the risk for developing a nonsteroidal antiinflammatory drug (NSAID) associated @entity360 prior to exposing @entity1 to therapy. METHODS: We conducted a retrospective cohort analysis using computer-stored information from a large group-model health maintenance organization. All @entity1 who received one or more prescriptions for a single NSAID over a 9 month period were eligible. Historical and risk factor data was obtained for age, sex, prior @entity360 , use of GI medications, @entity229 use, and use of disease modifying antirheumatic drugs (DMARD). We tested a model (eSCORE) that is based on a previous risk stratification method. The primary outcome was a hospital admission for a @entity360 (GI event). RESULTS: A total of 303,211 NSAID @entity1 -users met eligibility requirements. Serious GI events occurred in 302 @entity1 , for a rate of 0.68% (0.68 events per 100 @entity1 -years' exposure). All the risk factors except DMARD use were associated with a significant increase in the GI event rate. Higher eSCORE points were associated with increased GI event rates. CONCLUSION: The study supports the concept that the rate of GI events can be predicted by a defined set of easily assessed @entity1 criteria using the eSCORE. Stratification of @entity1 by risk score can guide the physician to appropriate therapeutic options, with the potential of protecting @entity1 at greatest risk for a GI event.
